MedTrace Logo

Luteal Phase Supplementation With Recombinant LH After GnRh Agonist Oocytes Triggering in Women at Risk of OHSS

NCT02200952 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2020-11-24

No results posted yet for this study

Summary

The purpose of this study is to prove that luteal phase supplementation with recombinant LH can solve the luteal phase deficiency after Gnrh agonist oocytes triggering in women at risk of OHSS

Conditions

  • Ovarian Hyperstimulation Syndrome

Interventions

DRUG

recombinant LH

recombinant LH twice/day for 10 days from pick up

Sponsors & Collaborators

  • San Carlo Public Hospital, Potenza, Italy

    lead OTHER

Principal Investigators

  • Assunta Iuliano, MD, PhD · San Carlo Public Hospital, Potenza, Italy

Eligibility

Min Age
18 Years
Max Age
43 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02200952 on ClinicalTrials.gov